Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery

NCT07234292 | Recruiting

• 1 other identifier: LT10100-001
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis). The participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.

Conditions

Eyelid; Wound

Outcome Measures

Primary Outcomes (1)

• global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied).

  3 months

Study Arms (1)

Group receiving Blephaderm

Other: Cosmetic: Blephaderm

Interventions

Cosmetic: Blephaderm OTHER

Preservative free eyelid cream: Aqua (water), oleyl erucate, trehalose, sodium acrylates copolymer, lecithin, Ophiopogon japonicus root extract, hydrolyzed hyaluronic acid, maltodextrin, tocopherol, sodium hydroxide, phytic acid, Glycine soja (soybean) oil, Helianthus annuus seed oil.

Group receiving Blephaderm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

A total of 30 patients undergoing blepharoplasty or ptosis surgery

You may qualify if:

• Age ≥ 18 years old
• Patients planning a blepharoplasty or a ptosis surgery in at least one eye.
• Patient affiliated to a health social security system
• Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.

You may not qualify if:

• In terms of population:
• Pregnant or nursing woman or planning a pregnancy during the study.
• Patient who had been deprived of their freedom by administrative or legal decision
• Minor patient.
• Major patient who is under guardianship or who is not able to express his non opposition.
• Patient suspected to be non-compliant according to the investigator's judgment.
• In terms of associated pathology
• Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk.
• Patient suffering from a severe or progressive disease.
• Patient with known or suspected hypersensitivity to one of the components of the product.
• Related to previous or ongoing treatment
• Patient undergoing a topical treatment on the test area or a systemic treatment.
• Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation.
• Patient under immunosuppressive therapy
• Patient under bisphosphonate therapy

Sponsors & Collaborators

• Laboratoires Thea: lead

Study Sites (1)

Pierre-Vincent Jacomet Private Practice

Paris, France

RECRUITING

MeSH Terms

Conditions

Wounds and Injuries

Central Study Contacts

Medical Affairs Director

CONTACT

+33 4 73 98 14 36; florence.noirt@theapharma.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2025
• First Posted: November 18, 2025
• Study Start: October 30, 2025
• Primary Completion (Estimated): December 15, 2026
• Study Completion (Estimated): December 15, 2026
• Last Updated: May 4, 2026

Record last verified: 2026-04

Locations

FR (1)